Knowledge is power when living with IBD.
Get access to the web’s leading IBD news & insights for as little as 16¢/day.Already a subscriber? Sign in here
FDA to Review Sandoz’s Application for Biosimilar to Bowel Disease Therapy Humira
The U.S. Food and Drug Administration has agreed to review Sandoz’s application for a biosimilar to AbbVie’s bowel disease therapy Humira (adalimumab). “When patients are dealing with a chronic disease, it is imperative they have access to important medication that will help best manage their health,” Mark Levick, Sandoz’s global head of development for biopharmaceuticals, said in a